23 related articles for article (PubMed ID: 38458039)
1. Prevalence and effect of
Ghosh A; Moorthy A
Saudi J Biol Sci; 2024 Aug; 31(8):104029. PubMed ID: 38873617
[No Abstract] [Full Text] [Related]
2. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Seiwert TY; Wildsmith S; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Baker V; Evans B; Morsli N; Jill Walker ; Real K; L'Hernault A; Psyrri A
Cancer Immunol Immunother; 2024 Mar; 73(4):70. PubMed ID: 38430375
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
4. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
Keam B; Hong MH; Shin SH; Heo SG; Kim JE; Ahn HK; Lee YG; Park KU; Yun T; Lee KW; Kim SB; Lee SC; Kim MK; Cho SH; Oh SY; Park SG; Hwang S; Nam BH; Kim S; Kim HR; Yun HJ;
J Clin Oncol; 2024 Feb; 42(5):507-517. PubMed ID: 37699162
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Han X; Zhang H; Sun K; Li J; Wu W; Liu K; Yu Z
Front Immunol; 2023; 14():1302840. PubMed ID: 38299153
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis.
Takenaka Y; Oya R; Takemoto N; Inohara H
Head Neck; 2022 May; 44(5):1237-1245. PubMed ID: 35146824
[TBL] [Abstract][Full Text] [Related]
8. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.
Lenze N; Chera B; Sheth S
Expert Opin Pharmacother; 2021 Feb; 22(2):135-144. PubMed ID: 33121281
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
11. Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
Kim DH; Lim ST; Kim HR; Kang EJ; Ahn HK; Lee YG; Sun S; Kwon JH; Lee SC; Lee HW; Kim MK; Keam B; Park KU; Shin SH; Yun HJ
Oral Oncol; 2024 Apr; 151():106739. PubMed ID: 38458039
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]